José M. Arencibia

1.3k total citations
33 papers, 1.1k citations indexed

About

José M. Arencibia is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, José M. Arencibia has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 9 papers in Oncology and 9 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in José M. Arencibia's work include Estrogen and related hormone effects (8 papers), Growth Hormone and Insulin-like Growth Factors (8 papers) and Lung Cancer Research Studies (7 papers). José M. Arencibia is often cited by papers focused on Estrogen and related hormone effects (8 papers), Growth Hormone and Insulin-like Growth Factors (8 papers) and Lung Cancer Research Studies (7 papers). José M. Arencibia collaborates with scholars based in United States, Germany and Italy. José M. Arencibia's co-authors include Andrew V. Schally, Gábor Halmos, Kate Groot, Jörg O. Schulze, Ricardo M. Biondi, Rodney Davis, David G. Bostwick, Daniel Pastor‐Flores, Attila Nagy and Zsuzsanna Kahán and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer and Cancer Research.

In The Last Decade

José M. Arencibia

32 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
José M. Arencibia United States	21	582	262	203	158	155	33	1.1k
Katarzyna Marta Lisowska Poland	16	736 1.3×	295 1.1×	85 0.4×	60 0.4×	280 1.8×	36	1.3k
Grégoire Prévost France	24	1.0k 1.7×	645 2.5×	111 0.5×	247 1.6×	14 0.1×	56	1.7k
Rodolfo A. Medina United Kingdom	15	563 1.0×	197 0.8×	96 0.5×	61 0.4×	20 0.1×	23	1.1k
Martin Eggert Germany	23	617 1.1×	136 0.5×	127 0.6×	60 0.4×	16 0.1×	41	1.2k
Mary P. Rosser United States	14	404 0.7×	256 1.0×	100 0.5×	30 0.2×	33 0.2×	22	877
Katja Wosikowski United States	17	459 0.8×	415 1.6×	48 0.2×	44 0.3×	16 0.1×	30	954
Guochen Yan United States	12	1.1k 2.0×	153 0.6×	80 0.4×	36 0.2×	25 0.2×	14	1.5k
Wolfgang Meißner Germany	14	811 1.4×	147 0.6×	40 0.2×	51 0.3×	42 0.3×	22	1.1k
Sally A. Prigent United Kingdom	16	775 1.3×	483 1.8×	42 0.2×	28 0.2×	20 0.1×	23	1.3k
Chen-Kung Chou Taiwan	18	646 1.1×	267 1.0×	42 0.2×	131 0.8×	12 0.1×	26	1.1k

Countries citing papers authored by José M. Arencibia

Since Specialization

Citations

This map shows the geographic impact of José M. Arencibia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José M. Arencibia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José M. Arencibia more than expected).

Fields of papers citing papers by José M. Arencibia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José M. Arencibia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José M. Arencibia. The network helps show where José M. Arencibia may publish in the future.

Co-authorship network of co-authors of José M. Arencibia

This figure shows the co-authorship network connecting the top 25 collaborators of José M. Arencibia. A scholar is included among the top collaborators of José M. Arencibia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José M. Arencibia. José M. Arencibia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arencibia, José M., Nicoletta Brindani, A. K. Jissy, et al.. (2020). Design, Synthesis, Dynamic Docking, Biochemical Characterization, and in Vivo Pharmacokinetics Studies of Novel Topoisomerase II Poisons with Promising Antiproliferative Activity. Journal of Medicinal Chemistry. 63(7). 3508–3521. 15 indexed citations

Catanzaro, Elena, José M. Arencibia, Serena Montanari, et al.. (2020). Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer. European Journal of Medicinal Chemistry. 202. 112504–112504. 32 indexed citations

Ortega, José Antonio, Laura Riccardi, José M. Arencibia, et al.. (2017). Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity. Journal of Medicinal Chemistry. 61(3). 1375–1379. 33 indexed citations

Arencibia, José M., Wolfgang Fröhner, Magdalena Krupa, et al.. (2017). An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms. ACS Chemical Biology. 12(2). 564–573. 18 indexed citations

Riccardi, Laura, et al.. (2017). Lid domain plasticity and lipid flexibility modulate enzyme specificity in human monoacylglycerol lipase. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1862(5). 441–451. 19 indexed citations

Schmithals, Christian, Verena Köberle, Hüdayi Korkusuz, et al.. (2015). Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. Cancer Research. 75(15). 3147–3154. 54 indexed citations

Zhang, Hua, Sonja Neimanis, Laura A. Lopez-Garcia, et al.. (2014). Molecular Mechanism of Regulation of the Atypical Protein Kinase C by N-terminal Domains and an Allosteric Small Compound. Chemistry & Biology. 21(6). 754–765. 20 indexed citations

Arencibia, José M., et al.. (2013). AGC protein kinases: From structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1834(7). 1302–1321. 140 indexed citations

Busschots, Katrien, Laura A. Lopez-Garcia, Carmen Lammi, et al.. (2012). Substrate-Selective Inhibition of Protein Kinase PDK1 by Small Compounds that Bind to the PIF-Pocket Allosteric Docking Site. Chemistry & Biology. 19(9). 1152–1163. 67 indexed citations

10.

Arencibia, José M., M. Del Rı́o, Ana Bonnin, et al.. (2005). Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation.. PubMed. 27(6). 1617–23. 18 indexed citations

11.

Arencibia, José M., Ana M. Bajo, Andrew V. Schally, et al.. (2002). Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti-Cancer Drugs. 13(9). 949–956. 20 indexed citations

12.

Arencibia, José M., Andrew V. Schally, Gábor Halmos, Attila Nagy, & Hippokratis Kiaris. (2001). In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses. Anti-Cancer Drugs. 12(1). 71–78. 17 indexed citations

13.

Arencibia, José M., Andrew V. Schally, Magdalena Krupa, et al.. (2001). Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. International Journal of Oncology. 19(3). 571–7. 23 indexed citations

14.

Płonowski, Artur, Andrew V. Schally, Miklós Koppán, et al.. (2001). Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer. 92(5). 1168–1176. 17 indexed citations

15.

Sun, Baodong, et al.. (2000). Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. Cancer. 88(6). 1384–1392. 21 indexed citations

16.

Kahán, Zsuzsanna, Attila Nagy, Andrew V. Schally, et al.. (2000). Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Research and Treatment. 59(3). 255–262. 26 indexed citations

17.

Halmos, Gábor, José M. Arencibia, Andrew V. Schally, Rodney Davis, & David G. Bostwick. (2000). HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. The Journal of Urology. 623–623. 9 indexed citations

18.

Kahán, Zsuzsanna, José M. Arencibia, Valér Csernus, et al.. (1999). Expression of Growth Hormone-Releasing Hormone (GHRH) Messenger Ribonucleic Acid and the Presence of Biologically Active GHRH in Human Breast, Endometrial, and Ovarian Cancers¹. The Journal of Clinical Endocrinology & Metabolism. 84(2). 582–589. 94 indexed citations

19.

Szepesházi, Károly, Gábor Halmos, Andrew V. Schally, et al.. (1999). Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. Journal of Cancer Research and Clinical Oncology. 125(8-9). 444–452. 36 indexed citations

20.

Koppán, Miklós, et al.. (1998). Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.. PubMed. 58(18). 4132–7. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact